「by」の検索結果
76件：21～25件目を表示
-
学会发表 | 研究与开发 | 千寿制药株式会社
orado, United States of America Motugivatrep suppresses the expression of proinflammatory mediators by inhibiting TRPV1 activation mediated by hyperosmotic and inflammatory stimuli in human corneal ep...
http://www.senju.co.jp/chinese/rd/society/ -
that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction by pharmacist, hereinafter this "Product") from Ministry of Health, Labour and Welfare. Th...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903.pdf -
临床试验信息 | 研究与开发 | 千寿制药株式会社
Completed jRCT2031210280 Disclaimer This website provides information on clinical trials sponsored by SENJU PHARMACEUTICAL Co., Ltd. (hereinafter referred to as “SENJU”) to the public including patie...
http://www.senju.co.jp/chinese/rd/trial.html -
ical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of RET-700 in Japan, effective immediately (medical device a...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240726.pdf -
NewMytear A | OTC Products, etc. | Products | SENJU Pharmaceutical
ysician, pharmacist, or registered salesperson* before using this medicine: Persons under treatment by a physician Persons who have had allergies to medicines or something Persons who have suffered fr...
http://www.senju.co.jp/english/products/myteara.html